REG - Abingdon Health PLC - Launch of seaweed-based lateral flow housings

Abingdon HealthAnnouncement

06/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251106:nRSF3869Ga&default-theme=true

RNS Number : 3869G  Abingdon Health PLC  06 November 2025

6 November 2025

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON
THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE,
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Launch of seaweed-based lateral flow housings

Alternative to standard plastic housings to reduce plastic waste from LFTs

 

Abingdon Health plc (AIM: ABDX), a leading international developer,
manufacturer and regulatory services provider for rapid diagnostic tests and
med-tech, announces the launch of a seaweed-based alternative housing for its
contract development and manufacturing (CDMO) customers for the development
and manufacture of lateral flow tests (LFTs).

 

The Company has agreed an exclusive supply agreement with Wolverhampton based
Symbio Technologies Ltd (https://www.symbio-tex.com/) ("SymbioTex") for the
supply of compostable bio-based material derived from red-seaweed which can be
used to produce lateral flow cassettes via standard injection moulding
techniques. This option will provide an alternative to the standard plastic
houses that are currently used and create opportunity for Abingdon customers
to significantly reduce their plastic waste.

 

The Company has developed prototype cassettes in both standard format and in
mid-stream urine sample format as is used for pregnancy and fertility testing.

     Examples of the Company's seaweed-based housings with, on the left side, a
     positive (left) and negative (right) test for the plant disease Phytopthora
     spp from the Company's Pocket Diagnostic® (https://www.pocketdiagnostic.com/)
     range using blue latex as signal.

     And on the right side, positive (left) and negative (right) pregnancy tests
     using colloidal gold label in seaweed-based housings in mid-stream urine
     format as used in pregnancy and fertility testing.

 

Olivia Simpson, Managing Director of SymbioTex, commented: "SymbioTex is
delighted to have agreed the exclusive supply of our seaweed-based home
compostable biomaterial to Abingdon Health. It is a truly home compostable,
sustainable material that can be used to revolutionise the production of
packaging and medical devices currently made from single-use plastic."

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "LFTs are
crucial for rapid diagnostic testing with over 2 billion used annually across
the globe. However, this generates greater than 20,000 tonnes of plastic
waste. By offering a plastic free rigid cassette in a range of formats,
Abingdon Health aims to help our CDMO customers reduce plastic waste without
compromising on the functionality of the tests. The use of SymbioTex's
material, as well as harnessing the power of renewable natural resources,
gives us the practical benefit of using traditional plastic injection
moulding machinery thereby easing the development pathway".

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR
 Tom Hayes, CFO

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Jacob Walker (Corporate Finance)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                   Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
expertise offers lateral flow product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health has the internal capabilities to take lateral
flow projects, in areas such as infectious disease and clinical testing,
including companion diagnostics, animal health and environmental testing, from
initial concept through to routine manufacturing; from "idea to commercial
success".  Abingdon Analytical Ltd offers performance evaluation for lateral
flow and other in vitro diagnostic assays from its Doncaster laboratory.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFFTLLLEIIE



            Copyright 2019 Regulatory News Service, all rights reserved